Figueroa, David J.
GlaxoSmithKline (United States)
2 papers on CoChatORCID 0009-0009-6442-0104
Most cited papers
- Verified
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., et al. (2013) · Cancer Research
Endoplasmic Reticulum Stress and DiseasePI3K/AKT/mTOR signaling in cancer
Cited by 443
- Verified
Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2
Willette, R. N., Bao, W., Nerurkar, S., Yue, T.-L., Doe, C. P., Stankus, G., Turner, G. H., Ju, H., Thomas, H., Fishman, C. E., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics
Ion Channels and ReceptorsNitric Oxide and Endothelin Effects
Cited by 300
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free